NICE flip-flops to recommend Novartis' Farydak; Novo incentives for plant may exceed $130M;

@FiercePharma: Flu expert warns against USDA move to build bird flu vaccine stockpile. Article | Follow @FiercePharma

@CarlyHFierce: @RepCummings to Shkreli: "To claim that a 50% discount after a 5,000% increase is a 'price cut' is Orwellian double-speak." | Follow @CarlyHFierce

> The U.K.'s cost watchdogs have changed their mind on Novartis' ($NVS) myeloma med Farydak, recommending the drug after initially rejecting it for NHS use earlier this year. Report

> Teva ($TEVA), which has agreed to purchase Allergan's ($AGN) generics unit for $40.5 billion, has priced its public offerings of American depositary shares and mandatory convertible preferred shares. Release

> A report raises concerns about drug company employees doing health screenings at "health camps" in India where they hand out free medications. Story

> The incentives Novo Nordisk ($NVO) will get from North Carolina for investing $1.8 billion into a plant there could exceed $130 million. Story

> AstraZeneca ($AZN) will close an API plant in Bengaluru, India. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Syneron Medical bogged down with slumping sales for ultrasound fat-zapping device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's Dx Digest, featuring liquid biopsy news from Guardant Health and Circulogene Theranostics. Report | Follow @EmilyWFierce

> Novartis weighs sale of contact lens business as Alcon unit struggles to chart growth. More

> U.K.'s NHS funds 1,000+ patient trial of a minimally invasive artificial lung. Story

Biotech News

@FierceBiotech: Q&A: Philips on what's next after the first year of HealthTech. More from FierceMedicalDevices | Follow @FierceBiotech

@JohnCFierce: This week we've been seeing the venture cash flowing. Bodes well for lots more action in 2016. | Follow @JohnCFierce

> True North adds crossover investors in its $40M Series C. Article

> Kuros to merge with Cytos to gain entry to the Swiss Stock Exchange. Report

> FierceBiotech Radio on Gilead's maxed-out revenue and BioMarin's FDA struggles. More | Subscribe

CRO News

> Medidata reaches into South Korea with a CRO partnership. News

> Parexel revamps its trial management system for drugmakers large and small. Report

> INC's financiers bank another $272M in the IPO afterglow. More

> Survey: CRO employee turnover soars amid an industry boom. Story

> Quotient Clinical snapped up by Gillings-founded buyout firm. Article

Pharma Manufacturing News

> Wockhardt says U.K. regulatory agency issued GMP certificate to troubled Chikalthana plant. News

> EU agency gives Baxalta green light to begin manufacturing two plasma-based therapies. Story

> Radiopharmaceutical manufacturer Iason Italia hit with noncompliance report. Article

> FDA cites two Endo subsidiaries for product recalls. Report

> Danaher acquires German quality inspection firm Laetus for undisclosed price. Item

Pharma Asia News

> India's GVK Bio gets infusion of cash from ChrysCapital. Item

> Generic drugs face April 2016 price caps in Japan. More

> Ascletis gets $20M from Goldman in race to China HCV approval. Report

> Singapore researchers close in on 'liquid biopsy' to track cancer progress, treatment. Story

> BMJ: Drugmakers get quid pro quo for participation in Indian health camps. Article

And Finally... Allergan CEO Brent Saunders, whose Ireland-based company just agreed to merge with Pfizer ($PFE), says his father gave him a hard time at Thanksgiving dinner for helping the pharma giant dodge higher U.S. taxes. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.